Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival?

Area of Science:

• Gynecologic Oncology
• Pathology
• Cancer Staging

Background:

• Endometrial stromal sarcomas (ESS) are rare uterine malignancies.
• Accurate staging is crucial for predicting prognosis and guiding treatment.
• The International Federation of Gynecology and Obstetrics (FIGO) introduced a new staging system for ESS.

Purpose of the Study:

• To evaluate the correlation between the new FIGO staging system and survival outcomes.
• To assess the system's effectiveness in risk stratification for stage I low-grade and high-grade ESS.
• To identify prognostic factors influencing survival in ESS.

Main Methods:

• Retrospective analysis of 464 patients from the Surveillance, Epidemiology, and End Results (SEER) database (1988-2005).
• Kaplan-Meier log rank and Cox proportional hazards models were employed for survival analysis.
• Comparison of survival rates between different stages and grades of ESS.

Main Results:

• The cohort comprised 310 low-grade, 96 high-grade, and 58 unclassified ESS.
• Five-year overall survival was significantly worse for high-grade ESS (45.4%) compared to low-grade ESS (97.2%).
• The new FIGO staging system showed significant prognostic value for low-grade ESS (IA vs. IB, p=0.003), but not for high-grade ESS (p=0.27).
• Prognostic factors for low-grade ESS included age, race, and stage; for high-grade ESS, only cervical involvement was significant.

Conclusions:

• The new FIGO staging system is appropriate for risk stratification in low-grade endometrial stromal sarcoma.
• Tumor size, a criterion in the new staging system, is less critical for high-grade ESS prognosis than cervical involvement.
• Cervical involvement is a key predictor of outcome in high-grade endometrial stromal sarcoma.